Literature DB >> 29130937

Amphiphysin (BIN1) negatively regulates dynamin 2 for normal muscle maturation.

Belinda S Cowling1,2,3,4, Ivana Prokic1,2,3,4, Hichem Tasfaout1,2,3,4, Aymen Rabai1,2,3,4, Frédéric Humbert5, Bruno Rinaldi6, Anne-Sophie Nicot1,2,3,4, Christine Kretz1,2,3,4, Sylvie Friant6, Aurélien Roux5,7, Jocelyn Laporte1,2,3,4.   

Abstract

Regulation of skeletal muscle development and organization is a complex process that is not fully understood. Here, we focused on amphiphysin 2 (BIN1, also known as bridging integrator-1) and dynamin 2 (DNM2), two ubiquitous proteins implicated in membrane remodeling and mutated in centronuclear myopathies (CNMs). We generated Bin1-/- Dnm2+/- mice to decipher the physiological interplay between BIN1 and DNM2. While Bin1-/- mice die perinatally from a skeletal muscle defect, Bin1-/- Dnm2+/- mice survived at least 18 months, and had normal muscle force and intracellular organization of muscle fibers, supporting BIN1 as a negative regulator of DNM2. We next characterized muscle-specific isoforms of BIN1 and DNM2. While BIN1 colocalized with and partially inhibited DNM2 activity during muscle maturation, BIN1 had no effect on the isoform of DNM2 found in adult muscle. Together, these results indicate that BIN1 and DNM2 regulate muscle development and organization, function through a common pathway, and define BIN1 as a negative regulator of DNM2 in vitro and in vivo during muscle maturation. Our data suggest that DNM2 modulation has potential as a therapeutic approach for patients with CNM and BIN1 defects. As BIN1 is implicated in cancers, arrhythmia, and late-onset Alzheimer disease, these findings may trigger research directions and therapeutic development for these common diseases.

Entities:  

Keywords:  Muscle Biology; Neuromuscular disease; Skeletal muscle

Mesh:

Substances:

Year:  2017        PMID: 29130937      PMCID: PMC5707152          DOI: 10.1172/JCI90542

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

1.  Activation of dynamin II by POPC in giant unilamellar vesicles: a two-photon fluorescence microscopy study.

Authors:  L A Bagatolli; D D Binns; D M Jameson; J P Albanesi
Journal:  J Protein Chem       Date:  2002-08

2.  Dynamin and the actin cytoskeleton cooperatively regulate plasma membrane invagination by BAR and F-BAR proteins.

Authors:  Toshiki Itoh; Kai S Erdmann; Aurelien Roux; Bianca Habermann; Hauke Werner; Pietro De Camilli
Journal:  Dev Cell       Date:  2005-12       Impact factor: 12.270

3.  Rapid purification of native dynamin I and colorimetric GTPase assay.

Authors:  Annie Quan; Phillip J Robinson
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

4.  Adult-onset autosomal dominant centronuclear myopathy due to BIN1 mutations.

Authors:  Johann Böhm; Valérie Biancalana; Edoardo Malfatti; Nicolas Dondaine; Catherine Koch; Nasim Vasli; Wolfram Kress; Matthias Strittmatter; Ana Lia Taratuto; Hernan Gonorazky; Pascal Laforêt; Thierry Maisonobe; Montse Olivé; Laura Gonzalez-Mera; Michel Fardeau; Nathalie Carrière; Pierre Clavelou; Bruno Eymard; Marc Bitoun; John Rendu; Julien Fauré; Joachim Weis; Jean-Louis Mandel; Norma B Romero; Jocelyn Laporte
Journal:  Brain       Date:  2014-09-25       Impact factor: 13.501

5.  Mice lacking microRNA 133a develop dynamin 2–dependent centronuclear myopathy.

Authors:  Ning Liu; Svetlana Bezprozvannaya; John M Shelton; Madlyn I Frisard; Matthew W Hulver; Ryan P McMillan; Yaru Wu; Kevin A Voelker; Robert W Grange; James A Richardson; Rhonda Bassel-Duby; Eric N Olson
Journal:  J Clin Invest       Date:  2011-08       Impact factor: 14.808

6.  Dynamin 2 mutants linked to centronuclear myopathies form abnormally stable polymers.

Authors:  Lei Wang; Barbara Barylko; Christopher Byers; Justin A Ross; David M Jameson; Joseph P Albanesi
Journal:  J Biol Chem       Date:  2010-06-07       Impact factor: 5.157

7.  Sequential docking, molecular differentiation, and positioning of T-Tubule/SR junctions in developing mouse skeletal muscle.

Authors:  H Takekura; B E Flucher; C Franzini-Armstrong
Journal:  Dev Biol       Date:  2001-11-15       Impact factor: 3.582

8.  The myotubularin-amphiphysin 2 complex in membrane tubulation and centronuclear myopathies.

Authors:  Barbara Royer; Karim Hnia; Christos Gavriilidis; Hélène Tronchère; Valérie Tosch; Jocelyn Laporte
Journal:  EMBO Rep       Date:  2013-08-06       Impact factor: 8.807

Review 9.  Neurotransmission and the synaptic vesicle cycle.

Authors:  Khashayar Farsad; Pietro De Camilli
Journal:  Yale J Biol Med       Date:  2002 Sep-Dec

10.  Phosphatase-dead myotubularin ameliorates X-linked centronuclear myopathy phenotypes in mice.

Authors:  Leonela Amoasii; Dimitri L Bertazzi; Hélène Tronchère; Karim Hnia; Gaëtan Chicanne; Bruno Rinaldi; Belinda S Cowling; Arnaud Ferry; Bruno Klaholz; Bernard Payrastre; Jocelyn Laporte; Sylvie Friant
Journal:  PLoS Genet       Date:  2012-10-11       Impact factor: 5.917

View more
  29 in total

1.  The intragenic microRNA miR199A1 in the dynamin 2 gene contributes to the pathology of X-linked centronuclear myopathy.

Authors:  Xin Chen; Yun-Qian Gao; Yan-Yan Zheng; Wei Wang; Pei Wang; Juan Liang; Wei Zhao; Tao Tao; Jie Sun; Lisha Wei; Yeqiong Li; Yuwei Zhou; Zhenji Gan; Xuena Zhang; Hua-Qun Chen; Min-Sheng Zhu
Journal:  J Biol Chem       Date:  2020-04-29       Impact factor: 5.157

Review 2.  The role of junctophilin proteins in cellular function.

Authors:  Stephan E Lehnart; Xander H T Wehrens
Journal:  Physiol Rev       Date:  2022-01-10       Impact factor: 37.312

3.  Reducing dynamin 2 (DNM2) rescues DNM2-related dominant centronuclear myopathy.

Authors:  Suzie Buono; Jacob A Ross; Hichem Tasfaout; Yotam Levy; Christine Kretz; Leighla Tayefeh; John Matson; Shuling Guo; Pascal Kessler; Brett P Monia; Marc Bitoun; Julien Ochala; Jocelyn Laporte; Belinda S Cowling
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-05       Impact factor: 11.205

4.  Multi-omics comparisons of different forms of centronuclear myopathies and the effects of several therapeutic strategies.

Authors:  Sarah Djeddi; David Reiss; Alexia Menuet; Sébastien Freismuth; Juliana de Carvalho Neves; Sarah Djerroud; Xènia Massana-Muñoz; Anne-Sophie Sosson; Christine Kretz; Wolfgang Raffelsberger; Céline Keime; Olivier M Dorchies; Julie Thompson; Jocelyn Laporte
Journal:  Mol Ther       Date:  2021-05-01       Impact factor: 12.910

5.  Nanobar Array Assay Revealed Complementary Roles of BIN1 Splice Isoforms in Cardiac T-Tubule Morphogenesis.

Authors:  Lin-Lin Li; Qian-Jin Guo; Hsin-Ya Lou; Jing-Hui Liang; Yang Yang; Xin Xing; Hong-Tao Li; Jing Han; Shan Shen; Hui Li; Haihong Ye; Hao Di Wu; Bianxiao Cui; Shi-Qiang Wang
Journal:  Nano Lett       Date:  2020-08-10       Impact factor: 11.189

Review 6.  Molecular and cellular basis of genetically inherited skeletal muscle disorders.

Authors:  James J Dowling; Conrad C Weihl; Melissa J Spencer
Journal:  Nat Rev Mol Cell Biol       Date:  2021-07-13       Impact factor: 94.444

7.  Mice with muscle-specific deletion of Bin1 recapitulate centronuclear myopathy and acute downregulation of dynamin 2 improves their phenotypes.

Authors:  Roberto Silva-Rojas; Vasugi Nattarayan; Francisco Jaque-Fernandez; Raquel Gomez-Oca; Alexia Menuet; David Reiss; Marie Goret; Nadia Messaddeq; Valentina M Lionello; Christine Kretz; Belinda S Cowling; Vincent Jacquemond; Jocelyn Laporte
Journal:  Mol Ther       Date:  2021-08-08       Impact factor: 11.454

8.  Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy.

Authors:  Elinam Gayi; Laurence A Neff; Xènia Massana Muñoz; Hesham M Ismail; Marta Sierra; Thomas Mercier; Laurent A Décosterd; Jocelyn Laporte; Belinda S Cowling; Olivier M Dorchies; Leonardo Scapozza
Journal:  Nat Commun       Date:  2018-11-19       Impact factor: 14.919

9.  Tamoxifen therapy in a murine model of myotubular myopathy.

Authors:  Nika Maani; Nesrin Sabha; Kamran Rezai; Arun Ramani; Linda Groom; Nadine Eltayeb; Faranak Mavandadnejad; Andrea Pang; Giulia Russo; Michael Brudno; Volker Haucke; Robert T Dirksen; James J Dowling
Journal:  Nat Commun       Date:  2018-11-19       Impact factor: 14.919

Review 10.  A review of Dynamin 2 involvement in cancers highlights a promising therapeutic target.

Authors:  Delphine Trochet; Marc Bitoun
Journal:  J Exp Clin Cancer Res       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.